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B. Jack Longley1,3, Mohammad Athar4 and Vladimir S. Spiegelman1,2,3
Although the number of new cases of basal cell carcinoma (BCC) has increased rapidly in the last few decades,
the molecular basis of its pathogenesis is not completely understood. Activation of the Hedgehog (Hh) signaling
pathway has been shown to be a key factor driving the development of BCC. The Wnt/b-catenin signaling
pathway was also shown to be activated in BCCs and to perhaps modulate the activity of the Hh pathway. We
have previously identified a mechanism by which Wnt signaling regulates the transcriptional outcome of the Hh
signaling pathway. We demonstrated that coding region determinant-binding protein (CRD-BP), a direct target of
the Wnt/b-catenin signaling, binds to GLI1 mRNA, stabilizes it, and consequently upregulates its levels (mRNA
and protein) and activities. We hypothesized that Wnt-induced and CRD-BP-dependent regulation of GLI1
expression and activities is important for the development of BCC. In this study, we show that CRD-BP is
overexpressed in BCC and that its expression positively correlates with the activation of both Wnt and Hh
signaling pathways. We also describe the generation and characterization of a human BCC cell line. This cell line
was utilized to demonstrate the importance of CRD-BP-dependent regulation of GLI1 expression and activities in
the development of BCC.
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INTRODUCTION
Basal cell carcinoma (BCC) is the most common form of skin
cancer, affecting approximately 1 million Americans each
year. This cancer arises in the basal cells lining the deepest
layer of the epidermis. The vast majority of BCCs occur
sporadically, but immuno-compromised patients and patients
with the rare inherited disorder, basal cell nevus syndrome,
are more susceptible to developing BCC (Epstein, 2008). BCC
is more common in people over the age of 40. The majority of
BCC cases occur on those areas of the skin that are regularly
exposed to sunlight or other UVR. This includes the face, ears,
neck, scalp, shoulders, and back, although virtually every part
of the skin has been reported to be involved (Rippey, 1998).
Anyone with a history of sun exposure can develop BCC;
however, people with fair skin are at highest risk. Although the
death rate from BCC is low, as BCC rarely metastasizes
(Rippey, 1998), this malignancy is locally aggressive and if
untreated can destroy tissues, penetrating deeply to bone and
causing ulceration, loss of function, and disfiguration. BCC
therefore causes considerable morbidity and places a huge
burden on health-care service worldwide. The cost of care for
BCC is the fifth highest for all cancers in the Medicare
population in the United States (Epstein, 2008). Furthermore,
people who have BCC are at high risk of developing further
BCC lesions and other malignancies (Wong et al., 2003).
Although the number of new cases of BCC has increased
rapidly each year in the last few decades, the molecular basis
of its pathogenesis is not well understood. Aberrant regulation
of the Hedgehog (Hh) pathway contributes to the development
of BCC. Activating mutations of Smo or suppressing mutations
of Ptch have been shown to constitutively activate the Hh
signaling pathway (Wicking et al., 1999), and these mutations
have been observed in BCC. Patients with the autosomal,
dominant nevoid BCC syndrome carry disabling germline
mutations in one allele of the Ptch1 gene, and BCC from
these patients lacks the remaining, normal Ptch1 gene (Oro
et al., 1997). Activation of the Hh signaling pathway is also a
hallmark of sporadic BCC (Epstein, 2008). Transgenic mouse
models have provided further evidence that activation of
the Hh signaling pathway is a key step in the initiation of
the tumorigenic program leading to BCC (Xie et al., 1998;
Grachtchouk et al., 2000; Nilsson et al., 2000a,b; Tang et al.,
2004). In addition to Hh signaling, the Wnt/b-catenin
signaling pathway has been shown to be activated in BCC
(Doglioni et al., 2003; El-Bahrawy et al., 2003). Canonical
Wnt/b-catenin signaling is involved in the BCC tumorigenesis
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perhaps by modulating the Hh pathway activity (Yang et al.,
2008). Wnt and Hh are two major pathways that are critical in
embryonic development, stem cell maintenance, and
tumorigenesis. These two pathways have been postulated
to interact or cross-regulate at multiple levels; yet the
mechanisms of these interactions are not clear. In our
previous studies, we identified a novel mechanism by which
Wnt signaling regulates the transcriptional outcome of the Hh
signaling pathway. We demonstrated that Wnt/b-catenin
signaling induces expression of the Hh transcriptional
activator GLI1. We showed that coding region determinant-
binding protein (CRD-BP), a direct target of the Wnt/b-catenin
signaling (Noubissi et al., 2006), binds to the segment of
the coding region of GLI1 mRNA and stabilizes it. We also
showed that Wnt/b-catenin signaling induces the expression
and transcriptional activity of GLI1 in a CRD-BP-dependent
manner (Noubissi et al., 2009). In this study, we address the
question of whether CRD-BP-dependent regulation of GLI1
expression and activities is important to the development of
BCC. We show that CRD-BP is overexpressed in BCC and that
its expression positively correlates with the activation of both
Wnt and Hh signaling pathways. One of the hurdles in
elucidating the biology of BCC is the lack of human BCC
cell lines. We developed and characterized a novel human
BCC cell line in our lab. Using this cell line, we demonstrated
that CRD-BP-dependent regulation of GLI1 expression and
activities is important for the development of BCC.
RESULTS AND DISCUSSION
CRD-BP is overexpressed in BCC
In order to assess CRD-BP levels in BCC samples, RNA isolated
from 13 superficial BCCs was analyzed by quantitative reverse
transcriptase PCR. We observed an overexpression of CRD-BP
mRNA in 12 out of the 13 BCC samples compared with
matched controls (Figure 1a and b, Supplementary Figure S1a
and b online). In the same 12 samples characterized by
overexpression of CRD-BP, we also observed activation of both
Wnt and Hh signaling pathways indicated by the expression
levels of b-TrCP1, c-myc, AXIN, and TCF1 for the activation of
Wnt signaling, and the expression levels of GLI1, PTCH1, and
PTCH2 for the activation of Hh signaling (Figure 1a and b,
Supplementary Figure S1a online). Our results showed a strong
positive correlation between CRD-BP expression and the
expression of the genes that it regulates (b-TrCP1, c-myc, and
GLI1) in the BCC samples (Figure 1a). This observation was
further validated in another set of BCC samples where the range
of expression levels of CRD-BP was also higher in the 10 BCC
samples when compared with the range of its expression in the
unmatched normal skin controls (Supplementary Figure S1a
online). The expression levels of CRD-BP also correlated with
the activation of the Wnt and Hh signaling pathways in these
samples (Supplementary Figure S1a online).
Role of CRD-BP in the regulation of GLI-driven transcription,
growth, and apoptosis in hTERT-immortalized normal
keratinocytes
We previously showed that Wnt/b-catenin signaling stimulates
the transcriptional outcome of the Hh signaling pathway
(Noubissi et al., 2009). As expected, activation of the Wnt/b-
catenin signaling increases GLI promoter–dependent luciferase
activity in a CRD-BP-dependent manner in hTERT-immortalized
normal keratinocytes (Figure 2a). Our data also show that
overexpression of the PTCH mutant, which constitutively
activates the Hh signaling pathway (Barnes et al., 2005),
induces GLI promoter–driven luciferase activity in keratino-
cytes. Interestingly, knockdown of CRD-BP by specific small
hairpin RNA (shRNA) also inhibits PTCH mutant–dependent
increase in the GLI promoter–driven luciferase activity
(Figure 2a). These data suggest that stabilization of GLI1 mRNA
by CRD-BP is important for the regulation of GLI1 expression by
both Wnt and Hh signaling pathways. Conversely, overexpres-
sion of CRD-BP leads to an increase in the GLI promoter–driven
luciferase activity in the same cells (Figure 2b). We also
observed accelerated proliferation (Figure 2c–e) and inhibition
of apoptosis (Figure 2f) of the hTERT-immortalized normal
keratinocytes when CRD-BP was overexpressed.
Characterization of an established long-term human cell line
(UW-BCC1)
The absence of a characterized long-term human BCC cell
line has hindered the research progress in the study of BCC
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Figure 1. Analysis of the expression of coding region determinant-binding
protein (CRD-BP) and the activity of Wnt and Hedgehog (Hh) signaling
pathways in basal cell carcinoma (BCC). (a) Relative expression of CRD-BP,
GLI1, b-TrCP1, and c-myc in mRNA isolated from 13 superficial BCCs,
determined by quantitative reverse transcriptase-PCR. Each value represents
the ratio between the expression of each mRNA in BCC and its expression in
matching normal skin. (b) Relative expression of Tcf1, Axin, PTCH1, and
PTCH2 in mRNA isolated from 12 superficial BCCs, determined by
quantitative RT-PCR. Each value represents the ratio between the expression of
each mRNA in BCC and its expression in matching normal skin.
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biology. We, in our lab, have successfully established a long-
term human BCC cell line (UW-BCC1) (Figure 3a) (Materials
and Methods). The cell line is cultured in low-calcium media
used to establish normal epidermal keratinocytes. At passage
six, the karyotype of the cells was abnormal near triploid with
complex structural and numerical aberrations. This karyotype
remained unchanged at passage 39 (Supplementary Figure S2a
online). The assessment of the activity of the Hh pathway in
UW-BCC1 showed high levels of expression of the Hh
transcriptional activator GLI1 (Figure 3b and d), a remarkable
GLI promoter–driven luciferase activity (Figure 3e), and a
significant expression of endogenous GLI1 targets PTCH1 and
PTCH2 (Figure 3d). In addition, UW-BCC1 responded well to
the treatment with vismodegib, a small-molecule inhibitor of
smoothened recently approved by the Food and Drug Admin-
istration for the treatment of BCC (Figure 3f). These data
indicate that the Hh pathway is activated in this cell line.
UW-BCC1 shares some features of normal epidermal kerati-
nocytes, including the polygonal shape of the cells (Figure 3a)
and the significant expression of high–molecular weight kera-
tins (K5 and K14) (Figure 3c). Injection of UW-BCC1 in nude
mice induced tumor growth in 100% of animals with even as
little as 100,000 cells per injection, and addition of matrigel
enhanced in vivo growth (Table 1, Supplementary Figure S2b
online). Histologically, the xenografts grew in sheets and large
nests with sharp borders and central areas of necrosis. The
tumors fulfill cytologic criteria for BCC, including; (1) high
intercellular cohesion in tissue, (2) morphologically uniform
tumor cells, (3) high nuclear–cytoplasm ratio of tumor cells
with the cytoplasm forming a very narrow rim around the
nucleus, (4) oval or fusiform and sometimes round nuclei with
a smooth outline and evenly dispersed, finely dotted chroma-
tin, and (5) inconspicuous nucleoli (Supplementary Figure S2c
online). The Hh pathway is activated in the tumors as shown
by the expression levels of GLI1, PTCH1, and PTCH2
(Supplementary Figure S2d online). The Wnt pathway is also
activated in these tumors as indicated by the expression levels
of CRD-BP, b-TrCP1, and c-myc, which are Wnt targets
(Supplementary Figure S2d–g online). Keratins 5 and 14 are
significantly expressed in these tumors as well (Supplementary
Figure S2e-f online). Our data altogether show that we have
established a bona fide human BCC cell line.
Dependence of BCC cells on CRD-BP
We hypothesized that CRD-BP-dependent regulation of GLI1
expression and activities is important for the development of
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Figure 2. Coding region determinant-binding protein (CRD-BP) over-expression stimulates growth and inhibits apoptosis of hTERT-immortalized normal
keratinocytes. (a) Normal keratinocytes were grown in six-well plates and co-transfected with 830GLI BS-LucII reporter plasmid, pSV-40-galactosidase and
pcDNA3.1, b-catenin, PTCH mut, or b-catenin and PTCH-mut plasmids in the presence of scramble small hairpin RNA (shRNA) or CRD-BP shRNA as indicated.
In total, 48 hours after transfection, the luciferase activity was estimated using luciferase reporter assay reagent (Promega). b-Galactosidase was used for
normalization and estimated using b-galactosidase assay reagent. (b) The immortalized normal keratinocytes were grown in six-well plates and co-transfected with
8 30GLI BS-LucII reporter plasmid, pSV-40-galactosidase and pcDNA3.1 or CRD-BP plasmid. Forty-eight hours after transfection, the luciferase activity was
estimated using luciferase reporter assay reagent (Promega). b-Galactosidase was used for normalization and estimated using b-galactosidase assay reagent.
(e) hTERT-immortalized normal keratinocytes grown in 100-mm plates were co-transfected with pTK-puro plasmid (0.5mg) and pcDNA3.1 (9.5mg) or pTK-puro
plasmid (0.5mg) and CRD-BP (9.5mg) as indicated. Forty-eight hours after transfection, equal numbers of cells from each plate were seeded in five 100-mm plates
and treated with puromycin (5mg ml1) for 10 days. The colonies were counted under light microscope. (c) Immortalized normal keratinocytes grown in 100-mm
plates were transfected with pcDNA3.1 (10mg) or CRD-BP (10mg) as indicated. Twenty-four hours post transfection, 2,000 cells from each plate were seeded in
96-well plates. Growth assay was measured at 24, 48, and 72 hours post seeding. (d) A total of 1 million immortalized normal keratinocytes transfected as in c
were seeded in 100-mm plates and the cell growth was measured at 24, 48, and 72 hours using the TC10 automated cell counter from BioRad. (f) The
immortalized normal keratinocytes were transfected as in c. Twenty-four hours after transfection 2,000 cells from each plate was seeded in 96-well plates and
Caspase 3/7 was measured at 48 and 72hours post seeding. Each experiment was done at least twice and in triplicates. Each value represents mean±SD. *Pp0.05.
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BCC. CRD-BP is highly expressed in BCCs and in UW-BCC1
(Figures 1a and 3b, d, Supplementary Figures S1a–c and S3
online). Knockdown of CRD-BP with specific shRNA
(Noubissi et al., 2006) significantly inhibits the ability of
UW-BCC1 to form colonies (Figure 4a), and considerably
slows down its growth (Figure 4b). Knockdown of CRD-BP
also increases apoptosis in UW-BCC1 (Figure 4c), and inhibits
its ability to migrate through the membrane in the invasion
assay (Figure 4d). The effects of CRD-BP inhibition are more
pronounced than the effects of GLI1 inhibition. This is
expected as, in addition to GLI1, CRD-BP regulates other
genes involved in proliferation, invasion, and inhibition of
apoptosis, including b-TrCP1, c-myc, and other oncogenes
that might contribute to the development of BCC. Future
studies will delineate the role of CRD-BP in the pathogenesis
of BCC development in vivo.
In summary, our data suggest that CRD-BP may play a
critical role in BCC development: it is overexpressed in human
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Figure 3. Characterization of a human basal cell carcinoma (BCC) cell line (UW-BCC1). (a) UW-BCC1 in culture at passage 11 and at passage 73. A BCC sample
was sequentially trypsinized for 6, 12, and 18 hours in a humidified cell culture incubator with 5% CO2 and grown in low-calcium media as described in the
Supplementary Information. Bar¼ 30mm. (b) Protein expression of coding region determinant-binding protein (CRD-BP) and GLI1 in UW-BCC1 determined by
immunoblot analyses. b-Actin was used as internal control. This is a representative of three independent experiments. (c) Protein expression of keratin 5 and
keratin 14 in UW-BCC1 determined by immunoblot analyses. b-Actin was used as internal control. This is a representative of three independent experiments.
(d) Relative expression of CRD-BP, GLI1, PTCH1, and PTCH2 in mRNA isolated from UW-BCC1 and other cell lines determined by quantitative reverse
transcriptase-PCR. (e) UW-BCC1 and other cells as indicated were grown in six-well plates and co-transfected with 830GLI BS-LucII reporter plasmid and
pSV-40-galactosidase plasmid. Forty-eight hours after transfection, the luciferase activity was estimated using luciferase reporter assay reagent (Promega).
b-Galactosidase was used for normalization and estimated using b-galactosidase assay reagent (Pierce). Each experiment was done at least twice and in
triplicates. Each value represents mean±SD. *Pp0.05. (f) UW-BCC1 was grown in two 100-mm plates and transfected with pTK-puro plasmid. Equal numbers of
cells from each plate were seeded in five 100-mm plates. One set of plates was treated with Vismodegib (100 nM) for 72 hours and puromycin (5mg) for
10 days. The other set of plates was treated with puromycin (5mg) alone for 10 days. Colonies were counted under the microscope. Each experiment was done
at least twice and in triplicates. Each value represents mean±SD. *Pp0.05.
Table 1. Average tumor size in mm3 induced by UW-BCC1 injection in nude mice
Week 3 Week 4 Week 5 Week 6 Week 7
1 Million cells 249±18 943±188 — — —
500,000 cells 121±11 247±58 911±111 — —
100,000 cells Very tiny Small 39±4 229±24 874±140
Abbreviation: BCC, basal cell carcinoma.
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BCCs; it regulates the expression and activities of GLI1 and
other targets important for BCC tumorigenesis; and its down-
regulation suppresses the growth and tumorigenic properties
of BCC cells. Notably, the cell line generated in this study is
an asset for studying the biology of BCC and may be critical
for developing novel therapies.
Although it is absent or scarce in adult tissues, CRD-BP is de
novo activated and/or overexpressed in various neoplastic and
preneoplastic tumors (Leeds et al., 1997; Doyle et al., 1998;
Ioannidis et al., 2001; Ross et al., 2001; Ioannidis et al., 2004;
Ioannidis et al., 2003a, b), and its expression has been shown
to be associated with the most aggressive form of some
cancers (Gu et al., 2004; Ioannidis et al., 2004; Ioannidis
et al., 2003a, b). Our data indicate that CRD-BP is important
in BCC development, making CRD-BP an attractive target for
developing novel therapeutic approaches in the treatment of
BCC. Developing effective drugs for BCC treatment would
alleviate the cost of care for BCCs and would be a better
alternative to repeated surgical procedures, especially in the
case of basal cell nervous system and immuno-compromised
patients who are more prone to developing hundreds of BCCs
in their lifetime.
MATERIALS AND METHODS
BCC sample collection
BCC samples were collected from the UW Dermatology clinics. They
are biopsy-proven collected from BCC patients during Mohs surgery.
The matching normal skin tissues resulted from clear margin skin
obtained after closure of the wound. The samples were snap-frozen in
liquid nitrogen for RNA isolation and kept in culture media for cell
isolation. The protocol was reviewed and fully approved by the
University of Wisconsin, Health Science Institutional Review Board
(IRB).
RNA isolation and quantitative reverse transcriptase PCR
Total RNA from tissues or cells was isolated using TRI-Reagent
(Molecular Research Center, Cincinnati, OH).
Real-time PCR for quantitative measurement of CRD-BP, GLI1, b-
TrCP1, c-myc, TCF1, and AXIN was performed using the Advantage
RT-for-PCR kit (Clontech, Mountain View, CA) and SYBR Green Core
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Figure 4. Dependence of basal cell carcinoma (BCC) cells on coding region determinant-binding protein (CRD-BP). (a) UW-BCC1 cells grown in 100-mm
plates were co-transfected with pTK-puro plasmid (0.5mg) and irrelevant shRNA (9.5mg), pTK-puro plasmid and CRD-BP small hairpin RNA (shRNA; 9.5mg),
pTK-puro plasmid and GLI2 shRNA (9.5mg), or pTK-puro plasmid and GLI1 shRNA (9.5mg) as indicated. Forty-eight hours after transfection, equal number of cells
from each plate was seeded in five 100-mm plates and treated with puromycin (5mg ml1) for 10 days. The colonies were counted under the light microscope.
(b) UW-BCC1 cells grown in 100-mm plates were transfected with irrelevant shRNA (10mg), CRD-BP shRNA (10mg), GLI2 shRNA (10mg), or GLI1 shRNA (10mg) as
indicated. Twenty-four hours post transfection, 2,000 cells from each plate were seeded in 96-well plates. Growth assay was measured at 24, 48, and 72 hours post
seeding. (c) UW-BCC1 cells were transfected as in b. Twenty-four hours after transfection, 2,000 cells from each plate was seeded in 96-well plates. Caspase 3/7 was
measured at 48 hours post seeding. (d) UW-BCC1 cells were transfected as in b. In total, 2.5 104 cells from each plate were used for the invasion assay. Twenty-four
hours after transfection, cells suspended in low-serum media (1% fetal bovine serum) were added to the insert of the invasion plate and incubated for 48 hours
in a humidified incubator 10% FBS was used as chemoattractant. The cells were fixed with 10% formalin for 10 minutes at room temperature and lightly stained
with 0.5% crystal violet for 30 minutes. The non-invading cell/collagen layer from the interior of the inserts was removed and the cells bound to the membrane of the
insert were air-dried and counted under the microscope. Each experiment was done at least twice and in triplicates. Each value represents mean±SD. *Pp0.05.
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PCR reagents (Applied Biosystems, Foster City, CA). Primer sequences
are listed in Supplementary Table S1 online. Glyceraldehyde 3-
phosphate dehydrogenase was used as a reference gene. Quantitative
measurement of PTCH1 and PTCH2 was done using pre-designed
TaqMan gene expression assays (Applied Biosystems).
Establishment of UW-BCC1
UW-BCC1 was isolated from a superficial BCC that was removed
from the leg of a patient. The BCC sample was sequentially
trypsinized for 6, 12, and 18 hours in a humidified cell culture
incubator with 5% CO2 using 0.25% Trypsin per 2.21 mM EDTA
(Mediatech, Herndon, VA). The trypsinized cells were collected,
pooled together, and grown on an uncoated plate in EMEM with
nonessential amino acids and L-glutamine, but without calcium
(Lonza, Walkersville, MD). The medium was further supplemented
with epidermal growth factor (5 ng ml 1), bovine pancreas insulin
(5mg ml 1), transferrin (10 ng ml 1), ethanolamine (10mM), phospho-
ethanolamine (10mM), 0.02 mM calcium chloride, 7% fetal bovine
serum (FBS) (Sigma, St Louis, MO), and 1% penicillin–streptomycin–
amphotericin B (Mediatech).
We started with the serum media, and we alternated between serum
media and serum-free media (EpiLife cat# MEPI500CA, supplemented
with human keratinocyte growth supplement from Life Technologies
(Carlsbad, CA) EDGS cat# S-012-5). The media was changed every
other day. When the cells reached 70% confluency (B1.67 106
cells), they were plated at a density ofB5.57 105 per 100-mm plate
(1/3 of the cells). After the third passage, the cells were plated at a
density of B1.67 105 per 100-mm plate (1/10 of the cells) for
maintenance in the serum media. Using this method, our success rate
in establishing a BCC cell line was one out of a total of two attempts.
Cell lines and transfection
UW-BCC1, the melanoma cell lines sk-mel2 and sk-mel28 (ATCC,
Manassas, VA), and the hTERT-immortalized keratinocytes (Bhatia
et al., 2008) were transfected using Lipofectamine 2000 (Invitrogen,
Carlsbad, CA). Normal human epidermal keratinocytes (Invitrogen)
and normal human epidermal melanocytes (gift from Dr Setaluri)
were electroporated using the Lonza nucleofector kit (Lonza,
Walkersville, MD) according to the manufacturer’s recommendations.
Immunoblotting
The following antibodies were used for western blot analysis: anti-
GLI1, -K5, -K14, -b-actin (Santa Cruz Biotechnology, Santa Cruz, CA),
anti-CRD-BP mouse mAb (generated in our lab), and secondary
antibody conjugated with horseradish peroxidase (Chemicon,
Billerica, MA).
In order to obtain whole-cell lysates for western blot analysis, the
cells were lysed using a denaturing RIPA buffer containing phosphate-
buffered saline (pH 7.4), 0.5% sodium deoxycholate, 0.1% SDS, 1%
(v/v) IGEPAL, 100 mM sodium orthovanadate, and proteinase inhibitor
cocktail (Sigma). Frozen tissues were ground using pestle and mortar to
fine powder, and RIPA lysis buffer was added to it for homogenization
and the lysates were used for western blot. Immunoblotting procedures
were performed as described previously (Spiegelman et al., 2000).
Luciferase assay
Cells were co-transfected with 8 30GLI BS-LucII reporter plasmid
and pSV-40 b-galactosidase plasmid. GLI promoter–driven luciferase
activity was estimated 48 hours after transfection using luciferase
reporter assay reagent (Promega, Madison, WI). b-Galactosidase used
for normalization was estimated by the b-galactosidase assay reagent
(Pierce, Rockford, IL).
Immunostaining
Tissue sections cut from formalin-fixed paraffin-embedded tumors
were de-paraffinized in xylene (Fisher, Fair Lawn, NJ) and rehydrated
in grades of alcohol. The sections were subjected to antigen retrieval
by incubation in 10 mM citrate buffer in a microwave oven for
20 minutes. The sections were blocked with normal serum, probed
with specific primary antibodies to CRD-BP, b-catenin, or GLI1,
followed by the appropriate fluorescent-labeled secondary antibody
(Invitrogen). Tissue sections were mounted with Prolong Gold
Antifade with DAPI-mounting medium (Invitrogen).
Cytostaining
Cells were cultured on chamber slides and fixed with 10% formalin.
Nonspecific binding was averted by blocking in 10% BSA. Cells were
incubated at 4 1C overnight with CRD-BP, b-catenin (Millipore,
Billerica, MA), or GLI1 (Santa Cruz Biotechnology, Santa Cruz, CA)
antibodies. Slides were incubated with the appropriate secondary
antibody (Invitrogen) and mounted with Prolong Gold Antifade with
DAPI mounting medium (Invitrogen).
Cell proliferation assay
Cells were counted using the TC10 automated cell counter from Bio-
Rad (Hercules, CA) and an equal number of viable cells were plated
in 96-well plates. To measure cell proliferation, the MTS-based cell
proliferation assay kit was used (Promega). The assay was performed
every 24 hours and the incubation time was kept constant. The
intensity of the chromogenic substrate was measured at 490 nm.
Clonogenic assay
UW-BCC1 and the immortalized keratinocytes grown in 100-mm
plates were co-transfected with pTK-puro plasmid and any other
appropriate plasmid for the experiment. Forty-eight hours after
transfection, an equal number of cells from each plate were seeded
in five 100-mm plates and treated with puromycin (5mg ml 1)
(Sigma) for 14 days. Colonies were counted under a light microscope.
Detection of apoptosis
Apoptosis in UW-BCC1 and in the immortalized keratinocytes was
measured using the Caspase-Glo 3/7 assay kit (Promega) according to
the manufacturer’s recommendations.
Invasion assay
The invasion assay was performed using the BD BioCoat Growth
Factor Reduced BD MatrigelInvasion Chamber, 8.0mm PET Mem-
brane 24-well Cell Culture Inserts, packaged ready-to-use in BD
Falcon Companion Plates (BD Bioscience, San Jose, CA). The
chemoattractant used was 10% fetal bovine serum in the culture
media. In total, 2.5 104 cells suspended in low-serum media (1%
FBS) were added to the insert and incubated in a humidified
incubator for 48 hours. The cells were fixed with 10% formalin at
room temperature for 10 minutes and lightly stained with 0.5% crystal
violet for 30 minutes. The noninvading cells/collagen layers from the
interior of the inserts were removed, and the cells bound to the
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membrane of the insert were air-dried and counted under a
microscope.
Generation of tumors in nude mice
A total of 5 million UW-BCC1 cells at passage 6 were injected
subcutaneously with or without matrigel on the back of athymic nude
mice (Hsd:Athymic Nude-Foxn1, Harlan, Madison, WI). Each group
was composed of five 4-week-old male mice. Tumor growth was
monitored weekly, and tumor width, length, and depth were
measured using a caliper. The volume was calculated using the
formula described in Siddiqui et al. (2006).
Statistical analyses
The t-test was used for statistical analyses. Pp0.05 was considered
significant.
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